Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes.

[1]  J. Sun,et al.  IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells. , 1995, Journal of immunology.

[2]  M. Haider,et al.  Recombinant polymers for cancer gene therapy: a minireview. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[3]  V. Muzykantov,et al.  Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. , 2005, Current pharmaceutical design.

[4]  V. Muzykantov,et al.  Platelet-Endothelial Cell Adhesion Molecule-1-Directed Endothelial Targeting of Superoxide Dismutase Alleviates Oxidative Stress Caused by Either Extracellular or Intracellular Superoxide , 2007, Journal of Pharmacology and Experimental Therapeutics.

[5]  Charles P. Lin,et al.  Optical Imaging of the Adoptive Transfer of Human Endothelial Cells in Mice Using Anti-Human CD31 Monoclonal Antibody , 2007, Pharmaceutical Research.

[6]  F. He,et al.  Targeted delivery of therapeutic oligonucleotides to pulmonary circulation. , 2005, Advances in genetics.

[7]  Silvia Muro,et al.  Endothelial Targeting of High-Affinity Multivalent Polymer Nanocarriers Directed to Intercellular Adhesion Molecule 1 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[8]  R. Albrecht,et al.  Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[9]  Teruo Okano,et al.  Challenges in polymer therapeutics: state of the art and prospects of polymer drugs. , 2003, Advances in experimental medicine and biology.

[10]  V. Muzykantov,et al.  ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. , 2003, Blood.

[11]  V. Muzykantov,et al.  RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1. , 2008, Blood.

[12]  A. Goyal,et al.  Targeted intracellular delivery of therapeutics: an overview. , 2007, Die Pharmazie.

[13]  V. Muzykantov,et al.  Interaction of mAb to angiotensin-converting enzyme (ACE) with antigen in vitro and in vivo: antibody targeting to the lung induces ACE antigenic modulation. , 1994, International immunology.

[14]  E. Jones,et al.  Residues on Both Faces of the First Immunoglobulin Fold Contribute to Homophilic Binding Sites of PECAM-1/CD31* , 1997, The Journal of Biological Chemistry.

[15]  R. Stan.  Endocytosis pathways in endothelium: how many? , 2006, American journal of physiology. Lung cellular and molecular physiology.

[16]  S. Kennel,et al.  Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[17]  C. Edgell,et al.  Permanent cell line expressing human factor VIII-related antigen established by hybridization. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Dodia,et al.  Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme. , 1996, The American journal of physiology.

[19]  V. Muzykantov,et al.  ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. , 2005, Blood.

[20]  V. Muzykantov.  Targeting of superoxide dismutase and catalase to vascular endothelium. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[21]  D. Curiel,et al.  Selective rat lung endothelial targeting with a new set of monoclonal antibodies to angiotensin I-converting enzyme. , 2005, Pulmonary pharmacology & therapeutics.

[22]  Vladimir P Torchilin,et al.  Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. , 2006, Annual review of biomedical engineering.

[23]  J. Schnitzer.  gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. , 1992, The American journal of physiology.

[24]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[25]  R. Duncan,et al.  The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[26]  V. Muzykantov,et al.  PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[27]  V. Muzykantov,et al.  Cell‐selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  V. Muzykantov,et al.  Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. , 2008, Biomaterials.

[29]  Silvia Muro,et al.  Advanced drug delivery systems that target the vascular endothelium. , 2006, Molecular interventions.

[30]  R. Savani,et al.  Loss of PECAM-1 Function Impairs Alveolarization* , 2006, Journal of Biological Chemistry.

[31]  V. Muzykantov,et al.  A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1 , 2003, Journal of Cell Science.

[32]  V. Muzykantov,et al.  Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. , 2003, American journal of physiology. Cell physiology.

[33]  C. Berkland,et al.  Cell adhesion molecules for targeted drug delivery. , 2006, Journal of pharmaceutical sciences.

[34]  B. Engelhardt,et al.  PECAM-1/CD31 trans-homophilic binding at the intercellular junctions is independent of its cytoplasmic domain; evidence for heterophilic interaction with integrin alphavbeta3 in Cis. , 2000, Molecular biology of the cell.

[35]  I. Gurubhagavatula,et al.  Antibodies Against the First Ig-Like Domain of Human Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) That Inhibit PECAM-1-Dependent Homophilic Adhesion Block In Vivo Neutrophil Recruitment1 , 2000, The Journal of Immunology.

[36]  Hamidreza Ghandehari,et al.  Endocytosis and Interaction of Poly (Amidoamine) Dendrimers with Caco-2 Cells , 2007, Pharmaceutical Research.

[37]  Samir Mitragotri,et al.  Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  L. Cipelletti,et al.  Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. , 2002, Blood.

[39]  V. Muzykantov,et al.  Endothelial endocytic pathways: gates for vascular drug delivery. , 2004, Current vascular pharmacology.

[40]  T. Minko,et al.  Antibodies and peptides in cancer therapy. , 2006, Critical reviews in therapeutic drug carrier systems.

[41]  L. Medina-Kauwe.  “Alternative” endocytic mechanisms exploited by pathogens: New avenues for therapeutic delivery? , 2007, Advanced Drug Delivery Reviews.

[42]  B. Jacobson,et al.  Antibodies specific to the plasma membrane of rat lung microvascular endothelium. , 1997, Experimental cell research.

[43]  V. Muzykantov.  Biomedical aspects of targeted delivery of drugs to pulmonary endothelium , 2005, Expert opinion on drug delivery.

[44]  V. Muzykantov,et al.  Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. M. Lefer,et al.  In vivo regulation of PECAM‐1 activity during acute endothelial dysfunction in the rat mesenteric microvasculature , 1998, Journal of leukocyte biology.

[46]  D. Buerk,et al.  Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury , 2003, Nature Biotechnology.

[47]  W. Pardridge,et al.  Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.

[48]  A. Malik,et al.  Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung , 2001, The Journal of physiology.

[49]  H. DeLisser,et al.  Localization of multiple functional domains on human PECAM-1 (CD31) by monoclonal antibody epitope mapping. , 1995, Cell adhesion and communication.

[50]  V. Muzykantov,et al.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. , 2005, Blood.

[51]  J. Hanes,et al.  Characterization of the intracellular dynamics of a non-degradative pathway accessed by polymer nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[52]  N. Simionescu,et al.  Endothelial transport of macromolecules: transcytosis and endocytosis. A look from cell biology. , 1991, Cell biology reviews : CBR.

[53]  W. Muller,et al.  A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions , 1989, The Journal of experimental medicine.

[54]  S. Thom,et al.  Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. , 1993, Science.

[55]  J. Gorski,et al.  PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. , 1990, Science.